ECSP22074715A - Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos - Google Patents

Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos

Info

Publication number
ECSP22074715A
ECSP22074715A ECSENADI202274715A ECDI202274715A ECSP22074715A EC SP22074715 A ECSP22074715 A EC SP22074715A EC SENADI202274715 A ECSENADI202274715 A EC SENADI202274715A EC DI202274715 A ECDI202274715 A EC DI202274715A EC SP22074715 A ECSP22074715 A EC SP22074715A
Authority
EC
Ecuador
Prior art keywords
receptor agonist
agonist peptide
gip receptor
dosing
peptide compounds
Prior art date
Application number
ECSENADI202274715A
Other languages
English (en)
Inventor
Nicholas Scorah
Antoine Henninot
Derek Cole
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP22074715A publication Critical patent/ECSP22074715A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona compuestos peptídicos agonistas del receptor de GIP adecuados para dosificación una vez a la semana (QW), en los que dichos compuestos peptídicos tienen una acción activadora sobre los receptores de GIP, y el uso del péptido agonista del receptor de GIP como medicamento para el tratamiento y/o la prevención de la emesis o un síntoma o una afección asociados con la emesis. Específicamente, se proporciona un péptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las fórmulas (I)-(V) o una sal de este y un medicamento que lo comprende.
ECSENADI202274715A 2020-03-25 2022-09-23 Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos ECSP22074715A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062994721P 2020-03-25 2020-03-25

Publications (1)

Publication Number Publication Date
ECSP22074715A true ECSP22074715A (es) 2022-10-31

Family

ID=75674909

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202274715A ECSP22074715A (es) 2020-03-25 2022-09-23 Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos

Country Status (17)

Country Link
US (1) US20230143604A1 (es)
EP (1) EP4126920A2 (es)
JP (1) JP2023524603A (es)
KR (1) KR20220157409A (es)
CN (1) CN115916812A (es)
AR (1) AR121649A1 (es)
AU (1) AU2021243671A1 (es)
BR (1) BR112022019110A2 (es)
CA (1) CA3172241A1 (es)
CL (1) CL2022002597A1 (es)
CO (1) CO2022014960A2 (es)
EC (1) ECSP22074715A (es)
IL (1) IL296219A (es)
MX (1) MX2022011729A (es)
PE (1) PE20221727A1 (es)
TW (1) TW202202517A (es)
WO (1) WO2021193983A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
CA2660835A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR20130133103A (ko) * 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد

Also Published As

Publication number Publication date
WO2021193983A8 (en) 2023-05-25
EP4126920A2 (en) 2023-02-08
CN115916812A (zh) 2023-04-04
JP2023524603A (ja) 2023-06-12
AU2021243671A1 (en) 2022-10-13
PE20221727A1 (es) 2022-11-04
MX2022011729A (es) 2022-10-13
IL296219A (en) 2022-11-01
WO2021193983A3 (en) 2021-11-04
BR112022019110A2 (pt) 2023-01-17
WO2021193983A2 (en) 2021-09-30
AR121649A1 (es) 2022-06-22
TW202202517A (zh) 2022-01-16
CO2022014960A2 (es) 2022-11-08
CA3172241A1 (en) 2021-09-30
KR20220157409A (ko) 2022-11-29
CL2022002597A1 (es) 2023-06-02
US20230143604A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CO2019012271A2 (es) Péptido activador de receptor de gip
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CL2019000663A1 (es) Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1.
ECSP15044389A (es) Compuesto peptídico
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
BR112015023007A8 (pt) dispositivo de injeção de múltiplas câmaras
ECSP22074715A (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
CL2017001024A1 (es) Formulación de buprenorfina inyectable
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
AR106364A1 (es) Derivados de insulina y sus usos médicos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CO2022014959A2 (es) Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
CR20220553A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2018011353A2 (es) Dispositivo de inyección mecánico para descargar múltiples formulaciones líquidas, incluso vacunas
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
CO2020002967A2 (es) Desinfectante novedoso para criaderos